Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
TIMOLIDE 10-25 vs ALDOCLOR-250
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Timolol is a non-selective beta-adrenergic receptor antagonist that blocks beta-1 and beta-2 receptors, reducing heart rate, myocardial contractility, and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium and water, reducing plasma volume and blood pressure.
Aldoclor-250 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary output and reducing plasma volume.
Hypertension
Hypertension (first-line or adjunctive therapy),Off-label: Management of hypertensive crisis (as part of combination therapy)
One tablet (timolol 10 mg / hydrochlorothiazide 25 mg) orally once daily. May be increased to two tablets once daily if needed.
250 mg orally twice daily
The terminal elimination half-life of timolol is approximately 4 hours in patients with normal renal function, but may be prolonged to 12-20 hours in patients with renal impairment or hepatic dysfunction. The half-life of hydrochlorothiazide is 6-15 hours.
1.5-3 hours; prolonged in renal impairment (up to 20 hours with Cr Cl <10 m L/min).
Timolol is extensively metabolized in the liver primarily by CYP2D6; hydrochlorothiazide is not metabolized and is excreted unchanged in urine.
Methyldopa: Primarily hepatic metabolism via catecholamine pathways; conjugated to sulfate and other metabolites. Chlorothiazide: Not extensively metabolized; excreted unchanged in urine.
Timolol is primarily eliminated by renal excretion of unchanged drug and metabolites. Approximately 20% of a dose is excreted unchanged in urine, with the remainder as metabolites (mostly inactive). Fecal elimination accounts for less than 5%.
Renal (70-80% unchanged), biliary/fecal (15-25% as metabolites); total clearance ~250 m L/min.
Timolol is approximately 10-60% bound to plasma proteins (primarily albumin). Hydrochlorothiazide is about 40-70% bound to plasma proteins.
25-40% bound primarily to albumin and alpha-1-acid glycoprotein.
Timolol: Vd approximately 1.3-3.6 L/kg, indicating extensive tissue distribution. Hydrochlorothiazide: Vd approximately 0.8-1.2 L/kg.
0.6-1.0 L/kg; indicates distribution into total body water and some tissue binding.
Oral bioavailability of timolol is approximately 50-75% due to first-pass metabolism. Hydrochlorothiazide bioavailability is about 65-70%. Ophthalmic timolol undergoes systemic absorption, with measurable plasma levels.
70-90% (oral); 100% (IV).
GFR 30-50 m L/min: maximum dose of timolol 10 mg/hydrochlorothiazide 25 mg once daily. GFR <30 m L/min: contraindicated (hydrochlorothiazide ineffective, risk of thiazide accumulation).
Cr Cl >50 m L/min: no adjustment; Cr Cl 10-50 m L/min: 250 mg once daily; Cr Cl <10 m L/min: 250 mg every 48 hours
Child-Pugh A: no adjustment. Child-Pugh B: reduce dose; start with lowest dose (timolol 10 mg/hydrochlorothiazide 25 mg) and titrate cautiously. Child-Pugh C: contraindicated (risk of hepatic encephalopathy and beta-blocker toxicity).
Child-Pugh A: no adjustment; Child-Pugh B: use with caution, reduce dose by 50%; Child-Pugh C: avoid use
Not recommended; safety and efficacy not established in pediatric patients.
Not recommended for use in pediatric patients due to lack of safety and efficacy data
Start with lowest dose (timolol 10 mg/hydrochlorothiazide 25 mg once daily); monitor renal function, electrolytes, and heart rate. Avoid in patients with significant bradycardia or heart block.
Start at lower end of dosing range; monitor renal function closely; adjust dose based on Cr Cl
No FDA black box warning.
None explicitly listed. However, methyldopa carries a warning for hepatotoxicity and hemolytic anemia; chlorothiazide carries a warning for electrolyte disturbances and hypersensitivity reactions.
Exacerbation of angina or myocardial ischemia upon abrupt withdrawal,Bronchospasm in patients with asthma or COPD,Masking of hypoglycemia in diabetic patients,Electrolyte imbalances, hypokalemia, hypercalcemia, hyperuricemia due to hydrochlorothiazide,Fetal harm if used during pregnancy
Hepatotoxicity (methyldopa), hemolytic anemia, positive direct Coombs test, sedation, depression, bradycardia, orthostatic hypotension, electrolyte imbalance (hypokalemia, hyponatremia, hypomagnesemia), hyperuricemia, hyperglycemia, photosensitivity, lupus-like syndrome, and hypersensitivity reactions.
Bronchial asthma,Sinus bradycardia,Heart block greater than first degree,Cardiogenic shock,Overt cardiac failure,Anuria,Hypersensitivity to timolol or hydrochlorothiazide
Active hepatic disease, history of previous methyldopa-induced liver dysfunction, hemolytic anemia associated with methyldopa, anuria, hypersensitivity to methyldopa, chlorothiazide, or sulfonamide-derived drugs, severe renal impairment (Cr Cl <30 m L/min), and concomitant therapy with MAO inhibitors.
Avoid high-potassium foods (e.g., bananas, oranges, potatoes) as hydrochlorothiazide can cause potassium loss, but timolol may mask hyperkalemia. Limit salt intake to enhance blood pressure control. Consume alcohol moderately as it may potentiate hypotension. Take with food to reduce gastrointestinal upset.
Avoid high-potassium foods (bananas, oranges, spinach) unless specifically advised; chlorothiazide may cause potassium loss, but methyldopa can cause potassium retention. Avoid excessive alcohol intake as it may potentiate hypotension. Take with food to reduce gastrointestinal upset. May decrease glucose tolerance; monitor in diabetic patients.
First trimester: Risk category D. Timolol (beta-blocker) and hydrochlorothiazide (diuretic) are associated with potential fetal bradycardia, hypoglycemia, and growth restriction. Thiazides may cause fetal electrolyte imbalances and jaundice. Second and third trimesters: Continued risk of fetal bradycardia, reduced placental perfusion, and neonatal complications (hypoglycemia, bradycardia, respiratory depression). Thiazides may cause oligohydramnios and neonatal thrombocytopenia.
FDA Pregnancy Category D. First trimester: Associated with cardiovascular defects (e.g., VSD), neural tube defects, and oral clefts. Second and third trimesters: Fetal nephrotoxicity (oligohydramnios, renal failure), premature closure of ductus arteriosus, pulmonary hypertension, and intracranial hemorrhage. Avoid in third trimester.
Timolol is excreted into breast milk (M/P ratio approximately 1.4). Hydrochlorothiazide is also present in low amounts. Due to potential for infant bradycardia, hypoglycemia, and electrolyte disturbances, use during breastfeeding is generally not recommended. If essential, monitor infant for signs of beta-blockade and thiazide effects.
Chlorothiazide is excreted in breast milk; M/P ratio unknown. Can suppress lactation. Use only if maternal benefit outweighs potential infant risks (e.g., electrolyte disturbances, thrombocytopenia).
Pregnancy may alter pharmacokinetics of timolol due to increased plasma volume and renal clearance. Hydrochlorothiazide efficacy may be reduced due to increased GFR. Dose adjustments should be guided by clinical response but no standard dose modification; use lowest effective dose.
Increased volume of distribution and GFR in pregnancy may necessitate higher doses for equivalent effect. Start at lowest effective dose; titrate based on BP response. Monitor for hypokalemia and metabolic alkalosis.
Timolide 10-25 contains timolol (a non-selective beta-blocker) and hydrochlorothiazide (a thiazide diuretic). Monitor heart rate and blood pressure closely due to risk of bradycardia and hypotension. Avoid abrupt discontinuation to prevent rebound hypertension. Use with caution in patients with asthma, COPD, or diabetes as beta-blockers can mask hypoglycemia. Check electrolytes and renal function periodically due to diuretic effects.
Aldoclor-250 is a combination of methyldopa (250mg) and chlorothiazide. Methyldopa can cause a positive direct Coombs test (10-20% of patients) which may interfere with blood cross-matching; obtain a hematocrit and Coombs test before therapy and at 6 and 12 months. Chlorothiazide may cause hypokalemia; monitor potassium and consider potassium supplementation. Onset of methyldopa is 3-6 hours; delay full effect for 48-72 hours. Avoid use in patients with active liver disease or history of previous methyldopa-induced liver dysfunction.
Take this medication exactly as prescribed, usually once daily in the morning to avoid nighttime urination.,Do not stop taking this drug suddenly; consult your doctor before discontinuing to avoid a rapid rise in blood pressure.,Notify your doctor if you experience slow heartbeat, dizziness, fainting, or signs of electrolyte imbalance (e.g., muscle cramps, weakness, irregular heartbeat).,Avoid alcohol as it may increase dizziness or drowsiness.,Use caution when driving or operating machinery until you know how this medication affects you.,Keep all appointments for blood pressure and lab tests (e.g., potassium, sodium, kidney function).
Take exactly as prescribed; do not skip doses or stop suddenly.,May cause drowsiness or dizziness; avoid driving or operating machinery until you know how it affects you.,Rise slowly from sitting or lying to prevent lightheadedness.,Report any unexplained fever, jaundice, or dark urine immediately.,Use sun protection; this drug may increase sensitivity to sunlight.,Do not use potassium supplements or salt substitutes without consulting your doctor.,If you miss a dose, take it as soon as you remember unless it's near the next dose; do not double.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about TIMOLIDE 10-25 vs ALDOCLOR-250, answered by our medical review team.
TIMOLIDE 10-25 is a Antihypertensive Combination that works by Timolol is a non-selective beta-adrenergic receptor antagonist that blocks beta-1 and beta-2 receptors, reducing heart rate, myocardial contractility, and blood pressure. Hydrochlorothiazide is a thiazide diuretic that inhibits the sodium-chloride symporter in the distal convoluted tubule, increasing excretion of sodium and water, reducing plasma volume and blood pressure.. ALDOCLOR-250 is a Antihypertensive Combination (Central Alpha Agonist and Thiazide Diuretic) that works by Aldoclor-250 is a combination of methyldopa and chlorothiazide. Methyldopa is a centrally acting alpha-2 adrenergic agonist that reduces sympathetic outflow from the brain, decreasing peripheral vascular resistance and blood pressure. Chlorothiazide is a thiazide diuretic that inhibits sodium and chloride reabsorption in the distal convoluted tubule, increasing urinary output and reducing plasma volume.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between TIMOLIDE 10-25 and ALDOCLOR-250 depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of TIMOLIDE 10-25 is: One tablet (timolol 10 mg / hydrochlorothiazide 25 mg) orally once daily. May be increased to two tablets once daily if needed.. The standard adult dose of ALDOCLOR-250 is: 250 mg orally twice daily. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between TIMOLIDE 10-25 and ALDOCLOR-250 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. TIMOLIDE 10-25 is classified as Category C. First trimester: Risk category D. Timolol (beta-blocker) and hydrochlorothiazide (diuretic) are associated with potential fetal bradycardia, hypoglycemia, and growth restriction. T. ALDOCLOR-250 is classified as Category C. FDA Pregnancy Category D. First trimester: Associated with cardiovascular defects (e.g., VSD), neural tube defects, and oral clefts. Second and third trimesters: Fetal nephrotoxici. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.